ACP-105
Shop ACP-105 on KimeraChems · code GUIDE (10% off)Definition
ACP-105 is an investigational selective androgen receptor modulator (SARM) studied in laboratory settings for androgen receptor (AR) activity, with emphasis on skeletal muscle- and body-composition-focused research models. As a nonsteroidal androgen receptor ligand, ACP-105 is investigated for its ability to activate androgen receptor-mediated transcriptional signaling in ways that may differ from traditional anabolic androgens depending on the experimental model, dose, and duration of exposure. ACP-105 is not approved for human or veterinary use and is supplied strictly for laboratory and analytical research purposes.
Mechanism of Action
ACP-105 is studied as an androgen receptor agonist in experimental systems. Androgen receptor activation influences transcriptional programs involved in muscle protein balance, tissue remodeling, and metabolic regulation. Common areas of mechanistic investigation include
- Androgen receptor activation: Studied for its ability to bind the androgen receptor and regulate androgen-responsive gene transcription
- Anabolic signaling: Investigated for activation of pathways associated with skeletal-muscle maintenance and protein synthesis
- Tissue selectivity: Explored for differential androgen receptor activity across tissues depending on experimental model and exposure conditions
- Dose-dependent pharmacology: Studied for potential tradeoffs between tissue-selective signaling and broader androgenic effects as exposure increases
- Endocrine regulation: Longer-duration in vivo studies commonly evaluate downstream endocrine-feedback biomarkers during sustained androgen receptor activation
Areas of Investigation
ACP-105 is commonly studied in
- Lean-mass accrual and preservation in controlled experimental models
- Strength-related and performance-proxy endpoints in standardized training protocols
- Androgen receptor pharmacology and tissue-selectivity comparisons among SARMs
- Bone and connective-tissue biology in androgen-responsive research models
- Endocrine feedback and recovery following discontinuation in vivo
Safety Profile
Reported observations are model- and exposure-dependent and may include
- Suppression-like findings involving gonadotropin biomarkers in certain in vivo models
- Alterations in lipid-related biomarkers depending on exposure level and study duration
- Changes in hepatic-enzyme measurements in selected exposure paradigms or when combined with confounding interventions
- Androgenic findings in non-target tissues when tissue selectivity is exceeded or exposure is prolonged
- Uncertainty regarding long-term safety findings due to limited controlled data across species and study durations
Interaction Notes
ACP-105 is often explored alongside interventions that overlap with androgenic and anabolic signaling.
For educational purposes only. Not for human consumption.